Toucan Capital
Toucan Capital Corp. is a venture capital firm based in Bethesda, Maryland, specializing in seed and early-stage investments primarily in the life sciences and advanced technology sectors. Founded in 1998, the firm focuses on therapeutics, biologics, medical devices, immune therapy, regenerative medicines, and nanotechnologies. It seeks to invest in emerging technologies such as advanced materials, sensors, fuel cells, and information security. Toucan Capital typically invests between $0.01 million and $5 million in initial financing, often as a lead or co-lead investor in a company's first institutional funding. The firm is particularly active in the Mid-Atlantic region, where it aims to support companies that are often underserved by venture capital.
INmune Bio is a clinical-stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. By controlling residual disease, patients may live longer. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.
Reactive NanoTechnologies
Series D in 2008
Reactive NanoTechnologies, founded in 2001 and located in Hunt Valley, Maryland, specializes in the development and manufacture of products designed to control the instantaneous release of heat energy for advanced joining applications. Its offerings are utilized in various sectors, including concentrated photovoltaic systems, high-brightness LED attachment, power electronics, thermal management, and component mounting. Additionally, the company provides bonding processes for sputter targets and electronic assembly applications, enhancing the efficiency and reliability of these technologies.
Q Therapeutics
Venture Round in 2008
Q Therapeutics is a development stage company based in Salt Lake City, Utah, focused on creating human cell-based therapies for degenerative diseases affecting the brain and spinal cord. The company is primarily engaged in the development of Q-Cells, a novel stem cell therapy designed to treat a range of conditions, including amyotrophic lateral sclerosis (ALS), multiple sclerosis, transverse myelitis, traumatic spinal cord injury, and Parkinson's disease. Additionally, Q Therapeutics aims to address other neurological disorders such as Alzheimer’s disease, traumatic brain injury, cerebral palsy, leukodystrophies, central nervous system storage diseases, and peripheral neuropathies. The therapies developed by Q Therapeutics work by replacing the insulating myelin on damaged neurons and providing trophic support to restore and preserve normal neurological functions.
Reactive NanoTechnologies
Series C in 2008
Reactive NanoTechnologies, founded in 2001 and located in Hunt Valley, Maryland, specializes in the development and manufacture of products designed to control the instantaneous release of heat energy for advanced joining applications. Its offerings are utilized in various sectors, including concentrated photovoltaic systems, high-brightness LED attachment, power electronics, thermal management, and component mounting. Additionally, the company provides bonding processes for sputter targets and electronic assembly applications, enhancing the efficiency and reliability of these technologies.
Pepgen is a privately-held biopharmaceutical company that develops and commercializes novel products for the prevention and treatment of autoimmune and viral disorders. It was founded in 1992 by Chih-Ping Liu and is based in Alameda, California.
Intrapace
Series C in 2004
IntraPace, Inc. specializes in the development and marketing of implantable devices aimed at treating obesity. Founded in 2001 and located in Mountain View, California, the company has created the abiliti system, which stimulates a satiety response to facilitate weight loss. This innovative device is based on technology commonly used in cardiac pacemakers and defibrillators, allowing for implantation through standard laparoscopic methods. Notably, the abiliti system does not alter the digestive system's anatomy and imposes no restrictions on a patient's dietary intake, making it a versatile option for individuals seeking weight management solutions.
Reactive NanoTechnologies
Series B in 2004
Reactive NanoTechnologies, founded in 2001 and located in Hunt Valley, Maryland, specializes in the development and manufacture of products designed to control the instantaneous release of heat energy for advanced joining applications. Its offerings are utilized in various sectors, including concentrated photovoltaic systems, high-brightness LED attachment, power electronics, thermal management, and component mounting. Additionally, the company provides bonding processes for sputter targets and electronic assembly applications, enhancing the efficiency and reliability of these technologies.
Reactive NanoTechnologies
Series A in 2003
Reactive NanoTechnologies, founded in 2001 and located in Hunt Valley, Maryland, specializes in the development and manufacture of products designed to control the instantaneous release of heat energy for advanced joining applications. Its offerings are utilized in various sectors, including concentrated photovoltaic systems, high-brightness LED attachment, power electronics, thermal management, and component mounting. Additionally, the company provides bonding processes for sputter targets and electronic assembly applications, enhancing the efficiency and reliability of these technologies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.